ABSTRACT
Metallothioneins (MTs) are a family of low molecular weight proteins with a high affinity for divalent metals. Metallothionein has been shown to have a protective role in apoptosis. Specifically, it controls the cellular zinc ion levels. The proper intracellular Zn 2+ level maintains the fragmentation of DNA associated with caspase-3 activity. In cancer nests, MT has been identified in the peripheral regions and associated with higher cell proliferation rates and fewer positive apoptotic cells. The expression of MT in the stroma has been linked with tumor spread. The tumor stroma may respond to tumor growth and aggressiveness by the expression of MT, thus protecting itself from and developing a resistance to apoptosis. Multistep carcinogenesis is related to a breakdown in immune response that enables tumor progression and dissemination. This breakdown is a crucial for tumor survival. The evaluation of MT expression in cancer and its stroma seems to correlate with the level of immune system inhibition in cancer-adjacent stroma.
INTRODUCTION
The development of cancer is a multistep process. First, a cell acquires a malignant phenotype. In this stage, the accumulation of genetic alterations forms a molecular basis for the transformation from normal cell to cancer cell. For example, in a proposed model, ovarian cancer was demonstrated to arise from definite genetic alterations (mutations of TP53, hTERT, HRAS)(1). But genetic alterations were also identified in histopathologically healthy mucous membranes from tumor-adjacent tissue. Initially, the histological examinations performed on oral epithelium in 1953 by Slaughter et. al revealed that oral cancer developed from the multifocal areas of precancerous alterations that surrounded the tumor and in which second primary tumors would develop following surgical treatment. This abnormal tissue was defined as "field cancerization" (2). Later, genetic changes were discovered in this "field cancerization," also called "field effect". These genetic alterations were found in organs such as the oral cavity, oropharynx, larynx (3), lung (4), esophagus (5), vulva (6), cervix (7), colon (8), breast and bladder (9), and skin (10). A concept of "field cancerization" and a model of biological multistep carcinogenesis were thus proposed (11), (12) . In this model, a stem cell acquires one or more genetic alterations and forms a patch with genetically altered daughter cells; these escape from normal growth control and form a field, thus displacing normal epithelium. It is this field that develops into cancer (11) (12) . Further progression of the disease will depend upon the interaction between immune and cancer cells and is enabled by the phenomenon of tumor escape from host immunological surveillance. In patients with cancer, immune system function is disrupted. For example, in head and neck cancer patients, a decrease in the number and activity of TIL cells correlates with poor survival rates (13, 14, 15) . TILs were found to undergo spontaneous apoptosis via the Fas/FasL pathway and other death molecules (16, 17, 18) . Moreover, a significantly higher number of peripheral blood mononuclear cells undergoing apoptosis were found in head and neck cancer patients in comparison to healthy controls. It has been shown that these lymphocytes (19) were programmed to undergo apoptosis even though the symptoms of the disease were clinically absent in the patients from whom the lymphocytes were obtained (following surgery, and chemo-and radiotherapy). This effect was even more pronounced in patients prior to treatment. A tumor suppresses immune system activity not only locally, but also systemically, and this suppression has a long-term effect (19) . The final progression of the tumor is associated with the development of resistance to anticancer treatment.
Metallothioneins (MTs) are a family of low molecular weight proteins that have a high cystein content and a tri-dimensional structure together with a high affinity for divalent metals-both essential metals, such as zinc and copper, and toxic metals, such as cadmium and mercury (20, 21) . Mammalian metallothioneins include four isoforms. MT-1 and MT-2 are widely distributed in the tissues, while MT-3, MT-4 are found in specialized cells (21) . This metal-binding property is linked with MT's biological roles which include protection against metal toxicity, the donation of zinc and copper to metalloenzymes involved in apoptosis, production of gene transcription factors, and protection against oxidative stress (21) . MT may also play a role in cell proliferation and differentiation (21, 22) . The expression of MT in the cytoplasm is thought to be indicative of its protective role against cytotoxicity, while its nuclear expression is related to its ability to protect against genotoxicity (21) (22) (23) . Genotoxicity has to do with the cell's acquisition of the malignant phenotype, especially certain mutations that play a critical role in carcinogenesis. Cell cytotoxicity is important in the interactions that occur between immune cells and cancer cells. Both kinds of interactions are involved in the resistance to chemo-and radiotherapy. In sum, although MT was discovered more than 50 years ago, its many biological roles are not yet fully understood.
The MT antioxidant properties may include the interception of free radicals, complexation of redoxsensitive transition metals, and the alteration of zinc homeostasis or interaction with glutathione (GSH) (24) . The redox properties of MT are essential for buffering zinc ions in cellular signaling. MT is also an efficient scavenger of hydroxyl radicals. Yeast and mammalian MTs can functionally substitute for superoxide dysmutase in protecting yeast from oxidative stress. Expression of the mouse MT-I gene in response to zinc is regulated by the zinc-finger transcription factors (MTF-I) (25) . MTF-I is a metalloregulatory protein whose DNA-binding activity is reversibly activated in response to changes in free zinc concentration levels in the cell (25) . Cells which contain higher levels of MT expression are protected against heavy metal toxicity and oxidative stress, whereas underexpression in cell lines or in mice with null mutations of the MT-I and MT-II genes leads to increased susceptibility to cadmium toxicity and oxidative stress (25) . The redox status of the cell, measured by the ratio of reduced to oxidized glutathione and energy metabolism together, affects the binding and release of zinc from MT. An increase in oxidized glutathione in the cell can facilitate the release of zinc from MT. The metabolic enzyme activity can be transiently inhibited by redistributed zinc in the cells. Zinc may protect free thiols from oxidation and stabilize membranes, as well as restore activity to zincfinger proteins (25) .
METALLOTHIONEIN AND METAL IONS
Mammalian metallothionein can bind with metal ions in two distinct cluster structures: the first cluster, closer to the N-terminal, binds three metal atoms to nine cysteins; the second cluster, closer to the C-terminal, binds four metal atoms to eleven cysteins (21) . Cadmium and zinc induce metallothionein synthesis and bind avidly to MT (25) .
Zinc is an intracellular mediator of apoptosis which may interfere with the action of calcium (26) . Zinc prevents DNA fragmentation in many cell lines, inhibiting the calcium-magnesium dependent endonuclease (27) , while zinc chelation induces apoptosis in different cell lines (28) . Zinc specifically inhibits caspase-3, a protease implicated in apoptosis (29) . Changes in intracellular zinc levels are sufficient to alter susceptibility to apoptosis; in order to regulate tissue growth via molecular targets such as endonucleases and caspases proteases (30) , zinc may serve as a coordinating regulator of mitosis and apoptosis. A model has been proposed for zinc's regulatory role according to which it protects cells from apoptosis by maintaining caspase-3 and calcium/magnesium endonuclease in an inactive form in the resting state of the cell. Changes in zinc concentration and/or localization in the cell constitute the major step that may set off the cascade of events leading to cell death (31).
Cadmium is an environmental pollutant for most organisms; in mammals it is nephrotoxic, neurotoxic, and carcinogenic. It can induce cell death by either necrotic or apoptotic mechanisms. The induction of apoptosis by cadmium seems to trigger the mitochondrial pathway of apoptosis (32) . Furthermore, exposure to cadmium has been shown to increase endogenous bcl-2 protein sooner than would occur through metallothionein induction. Bcl-2 protein over-expression prevented not only cadmiuminduced apoptosis, but also the necrotic effects of cadmium (33) .
The anti-apoptotic effects of MT are highly dependent on cellular MT levels (34) . MT can provide protection from apoptosis regardless of the metal content of the protein as it is just as effective when induced by cadmium as by zinc (35) .
METALLOTHIONEIN AND APOPTOSIS
Apoptosis is a physiological process of programmed cell death. It occurs in such physiological events as embryogenesis (36) and the selection of lymphocytes in the thymus (37). Apoptosis is responsible for the regulation of cell populations in normal tissues and cell population increases in malignant neoplasms where it participates in tumor regression and ontogenesis (38) .
Apoptosis phases
Apoptosis is characterized by internucleosomal DNA fragmentation, chromatin condensation, and cytoplasmic blebbling with the formation of apoptotic bodies which are membrane-enclosed structures containing cytosol, condensed chromatin, and organelles (38) . As the cell dying by apoptosis is metabolically still active, the process often depends on RNA and protein synthesis (39) . DNA fragmentation is associated with the activity of DFF40 nuclease and with calcium/magnesium-dependent endonuclease which can be inhibited by zinc (40).
Apoptosis pathways
Caspases are proteolytic enzymes activated via various pathways in the early stage of apoptosis (41) . Two of the major pathways will be described here. The first is the caspase-8 pathway that mediates the extracellular signal of TNFα or FasL for the mitochondria, leading to the generation of activated caspase-8, as well as to the release of cytochrome c and the activation of procaspase-9. Activated caspases-8 and -9 are responsible for procaspases-3 and -7 activation. The second pathway involves chemical compounds, such as etoposide, which induce apoptosis by the direct activation of caspase-9 and leads to the activation of caspase-3 (31, 42) . The activation of caspase-3 seems to be an essential step in apoptosis. Casapse-3 is responsible for the activation of DNA fragmentation factor (DFF) which is composed of a 40kDa protein DFF40 with a nuclease activity and a 45 kDa protein inhibitory subunit DFF45 (43) . DFF45 has been demonstrated to be a substrate for caspase-3 during apoptosis (44).
Regulation of apoptosis
The phenomenon of apoptosis is regulated by a variety of factors. Apoptosis can be induced by mutagens, genotoxic anti-cancer drugs, ionizing irradiation, and nitric oxide, as well as other factors. Its inhibition is controlled by Bcl-2 and the antioxidants superoxide dysmutase and glutathione peroxidase (45) . Metallothionein has been shown to have a protective role in apoptosis. MT controls the cellular zinc ion level and thereby seems to modulate the functional activity of p53 protein (Figure 1) . p53 protein is a zinc-binding transcription factor that can either inhibit cell cycle progression or induce apoptosis in response to DNA damage or stress so that the damaged DNA can then be eliminated. Various mechanisms are responsible for the attenuation of functional p53 in cancer cells (46) . MT controls the intracellular distribution of zinc and acts as a potent chelator, removing zinc from p53 ( Figure 1 ). Zinc ions are essential for the maintenance of the wild type conformation and stability of p53 protein and its affinity for a specific DNA sequence (47) . Ostrakovitch et al. has observed that, in its apo-form (metal-free form), MT interacts with p53, and so has suggested that apo-MT/MT could be a control mechanism regulating p53 activity (48) . Persistent apo-MT over-expression in tumor cells may promote their accelerated growth and enhance their survival through the induction of a p53-null state (49) . MT may also protect cells against p53-mediated apoptosis (23) (Figure 1 ).
The cleavage of chromosomal DNA into nucleosomal units would seem to be the biochemical hallmark of apoptosis. The fragmentation of DNA is associated with caspase-3 activity, and this is maintained by the proper intracellular Zn 2+ level. A decrease in Zn
2+
leads to an increase in caspase-3 activity (31) , and conversely, Zn 2+ has been observed to inhibit caspase-3 activity (29) . The maintenance of the proper intracellular Zn 2+ level (34) is a function of MT (Figure 1) . The relation between an increase in the cytoplasmic MT level and a decrease in caspase-3 activity has also been identified with a decrease in mitochondrium-originating cytochrome c concomitant with the rise of MT expression in the cytoplasm. Kondo et al. has suggested that the rise in cytoplasmic MT expression observed during chemotherapy does not result directly from drug action, but rather from hormonal activity in the tumor microenvironment (24, 50) . Kondo has further proposed a possible complementary antiapoptotic interaction between MT and Bcl-2. A bilateral regulation between MT-2A and ECRG2 has been shown (51) . The ECRG2 gene expression product is responsible for the inhibition of the proliferation and induction of apoptosis, while MT intensifies proliferation and restricts apoptosis (51) . An increase in the spontaneous apoptosis level has been observed in mouse fetal cells deprived of MTI and MTII isoform genes (24, 50) .
MT has been found to be a negative regulator of NF-kappa B (nuclear factor kappa B) activity (52) . NFkappa B is a transcription factor; the activation of this factor is associated with HIAP (human inhibitor of apoptosis protein) which cuts IkB in cytoplasm. Consequently, the membrane receptors TNFR-1 (p55), CD40, DR3, DR4, and DR5, which possess the TNF receptor associated death domain (TRADD), are activated. An increase in NFκB expression has been associated with an increase in telomerase activity, and its participation in the promotion of tumor progression in squamous cell carcinoma has been demonstrated (53) . NFκB expression has also been shown to participate in the induction of drug resistance (54) . NFκB regulates pro-inflammatory cytokine gene expression through TNF-α (tumor necrosis factoralfa). NFκB also promotes tumor transformation and survival; it therefore participates in the acquisition of the malignant phenotype (53) . TNF-α may simultaneously induce the caspases cascade through the activation of NF-κB, which seems to be connected with the inhibition of apoptosis (55) . While MT inhibits TNF-dependent I-κB degradation affecting NF-κB activity, it may also regulate the transcription of NF-κB-related genes (52) . MT therefore seems to participate in the modulation of intracellular signal transduction that occurs after the activation of TNFR-1 and of cytoplasmic death domains (TRADD, RIADD), while MT over-expression has been found to confer resistance to the cytotoxic effects of TNF (56, 57) .
Bcl-2 family proteins are important regulators of apoptosis. Bcl-2 protein inhibits the apoptosis of proliferating human B lymphoma cells (58) . Other proteins from this family that inhibit apoptosis are Bcl-x L and A, while the proteins Bax and Bcl-x S induce apoptosis (59). The latter protein plays a major role in protecting cells from inappropriate apoptosis. Bcl-2 has been detected in the normal epithelia of the bronchi and the head and neck. Here the expression was localized in the basal membrane in cells thought to stem from epithelial cells. Bcl-2 has also been identified in malignant neoplasms (prostate, lung, and breast carcinomas), where bcl-2 expression correlated with the chance for survival of the patient (60-62). MT and Bcl-2 can rescue yeast mutants null toward superoxide dismutase from death after oxidant injury (63, 64) . It has been suggested that MT functionally complements the antiapoptotic protein Bcl-2 in yeast; however, there is no evidence that MT can complement Bcl-2 in higher eukaryotes (24, 50) .
METALLOTHIONEIN IN TUMORS
MT is highly expressed in many types of tumors and is involved in carcinogenesis. MT expression is considered to be cell-cycle dependent and is a marker for cell proliferation (49).
Proliferation, differentiation, and apoptosis
MT has been identified in both normal oral squamous epithelium and in tongue squamous cell carcinoma. In every case, MT was distributed in the basalparabasal layer of epithelial cells which are proliferating cells. In squamous cell carcinomas of the tongue, the presence of MT in the periphery of tumor nests was accompanied by fewer positive apoptotic cells and higher proliferation rates (65). MT was also found in the basal layer in the normal epithelium of the nasopharynx, as well as in nasopharyngeal carcinoma. An inverse correlation between MT expression and the apoptotic rate has been demonstrated (66) . Moreover, in nasopharyngeal cancer, a significant correlation has been identified between MT expression and positive Ki-67 (67) . Similarly, in breast cancer, MT 2A has been positively correlated with cell proliferation (a significant correlation was found between Ki-67 index and MT-2A protein expression) and tumor grade (68) . Furthermore, an inverse correlation between MT expression and the extent of apoptosis has been identified in Barrett's esophagus. In fact, MT expression increased with the progression of the histologic metaplasiadysplasia-adenocarcinoma sequence. It has been suggested that MT over-expression may protect Barrett's esophageal cells from apoptosis, ensuring their proliferation and the subsequent development of adenocarcinoma (69).
MT and survival
The survival rates for patients with MT-negative esophageal squamous cell carcinomas are better than those for patients with MT-positive tumors (70) . MT expression was identified in 45% of patients with lung small-cell carcinoma with a statistically significant higher overexpression in a short-term survival group that included patients with advanced disease and the probability for survival not exceeding 24 months (71) . MT overexpression in cases of ductal breast carcinoma was related to both lower survival rates and higher recurrence rates (72, 73) . A correlation of metallothionein isoform expression profile with the more invasive ER-negative breast cancer cells has also been identified (74) . In colorectal cancer, MT over-expression was a prognostic indicator of poor survival rate independent of major clinicopathological parameters (75) . In endometrial adenocarcinoma, high MT content has been associated with poor histological grade, reduced patient survival, and local tumor recurrence. Moreover, high MT intensity distribution scores have been identified in aggressive papillary serous adenocarcinoma (76).
MT and radiation injury
The protective effect of MT in radiation injury has been documented. MT synthesis was induced by ultraviolet irradiation in human skin in vivo, suggesting a physiological photo-protective role for MT (77) . Repeated doses of radiation exposure were more effective in inducing MT synthesis than one large dose. In normal cells, MT may provide a protective effect against radiation-induced genotoxicity and cytotoxicity, while in tumor cells, this phenomenon may participate in drug and radiation resistance (78, 79) . The presence of MT may be one of several factors involved in the radio-resistance of tumor tissue and the adaptive response in low-dose ionizing radiation (49) . In particular, Cai and Cherian discovered that MT bound to zinc had high-capacity antioxidant properties that protect cells from radiation-induced DNA damage (78, 79, 21) .
MT and drug protection
Acquisition of apoptotic resistance may be an important step in malignant transformation (80) . Sensitivity to drug-induced apoptosis is modulated by a number of factors, including tumor-suppressor proteins (p53, Bax) and the expression of anti-apoptotic proteins (bcl-2). The conferring of a multi-drug resistant phenotype by cancer cells is associated with the expression of drug efflux pumps (MDRs and MRPs) (35) . MT has been correlated with resistance to apoptosis induced by doxorubicin in cardiomyocytes (81) . Cells that lack MT due to gene deletion are more sensitive to the cytotoxicity of anticancer drugs, mutagens, and oxidants (24) . MT has also been found to protect cells from apoptosis induced by etoposide (35) . In cases of esophageal squamous cell carcinoma, MT-negative tumors responded better to chemoradiotherapy (82) .
MT anti-apoptotic protective effects during chemotherapy and radiotherapy have two major consequences. On the one hand, they lead to resistance to the provided treatment, affecting the patient's chances for survival. On the other hand, they provide normal cell protection from negative chemotherapy and radiotherapy toxicity. From a clinical point of view, as far as the stimulation of MT expression in specific tissue is concerned, normal cells may be useful in preventing the side-effects of chemotherapy and radiotherapy, while the inhibition of MT expression in cancer cells may enhance the therapeutic response.
METALLOTHIONEIN IMMUNOMODULATING ACTIVITY
MT expression is induced by exposure to cellular stressors, such as heavy metal cations (83, 84) , reactive oxygen species (85) , and bacterial endotoxin (86) . MT can be released to the extracellular environment in response to these stressors and can be found in physiological fluids, such as blood, bile, and urine (87) . Furthermore, extracellular MT has been demonstrated to influence immune functions. Borghesi et al. has shown that MT present in the extracellular environment can interact with the plasma membrane of lymphocytes and modulate immune cell functioning (88) . MT can be induced by acutephase cytokines (IL-1, IL-6, TNF-alpha, IFN-gamma) (89, 90, 91) . MT has also been found to confer resistance to the TNF cytotoxic effect in MCF breast carcinoma cells (92) . MT suppressed murine cytotoxic lymphocyte function and decreased detectable MHC class I and CD8 molecules on lymphocytes, which are important for the interaction between CTL and target cells (93) . When the gradient chemotactic movement of leukocytes was demonstrated under metallothionein, MT appeared to modify the character of the immune response (94) . E. Canpolat et al. has proposed that MT could serve as a negative regulator of the immune response, suppressing the autoimmune attack on self-tissues. The induction of MT by glucocorticoids may explain the role of such treatment in autoimmune diseases. Nevertheless, a reportedly elevated MT synthesis in neoplasms may suppress the proper immune response in the tumor (95). Finally, MT may play a role in both the suppression of the anti-tumor response and in the increase in tumor cell proliferation.
METALLOTHIONEIN IN STROMA
MT expression has been reported in both healthy and cancerous tissues. In healthy tongue epithelium, the expression of MT was typically localized in basal and parabasal cells, which are known to be the dividing cells; in the more superficial areas of epithelium where the cells are differentiated MT expression was lacking (65). Likewise, MT expression in healthy head and neck epithelium was reported to be typically localized in the parabasal layer of the epithelium (96) (97) (98) (99) . MT has also been reportedly expressed in healthy tissues adjacent to a tumor in lung cancer (100) and in the stroma of head and neck carcinoma (squamous cell carcinomas of oral cavity, pharynx, and maxillary sinus) (101). MT immunoreactivity in head and neck squamous cell carcinomas and breast adenocarcinomas has been reportedly expressed by healthy tumor-adjacent tissue even in cases where the cancer cells did not express MT (96) (97) (98) (99) . MT has been found in healthy cartilage in the vicinity of head and neck cancer. In breast cancer, MT expression has been identified in a tumor-adjacent healthy vascular wall, while healthy gland cells in the tumor vicinity also expressed MT. It has been suggested that cancer cells migrating from the tumor may induce a response of MT expression in adjacent tissues (96) (97) (98) . MT expression in tumor cells would seem to be associated with an increased resistance to apoptosis induced by infiltrating immune cells. The interaction between tumor cells and immune cells involves tumor escape from host immunological surveillance. Tumor cells express agents which, on the one hand, are able to inhibit the activity of infiltrating immune cells, but, on the other hand, protect tumor cells from unwanted apoptosis. MT expression by tumor -adjacent tissue may also be associated with increased tumor aggressiveness, local tumor spread, and the response to an increasing accumulation of immune cytotoxic cells in tumor microenvironments. MT expression in healthy tumor-adjacent tissue has been shown to be significantly higher in patients with lymph node metastases (98) . Thus the expression of MT in the stroma has been associated with tumor spread. The tumor stroma may respond to the tumor growth and aggressiveness by the expression of MT, thus protecting itself from and developing a resistance to apoptosis (Figure 2 ).
METALLOTHIONEIN IN DECIDUA
Alterations in apoptotic levels in the endometrium corresponding to menstrual cycle changes and to the respective layers of the endometrium have been observed (102) . Endometrial ectopic cells typically have a different apoptotic level than eutopic endometrial cells (103). This phenomenon is probably linked to alterations in the eutopic endometrium profile of immune cell infiltration and to unique feature of endometrial cells (104) (105) (106) (107) (108) (109) (110) (111) (112) . The mucous membrane of the entire reproductive tract is infiltrated by immune system cells and activated immune cytotoxic cells are predominant in this infiltrate (NK cells in the endometrium and CTLs in the tubal mucosa) (104) . The activity of these infiltrating immune cells (113) (114) (115) (116) is regulated by mucous membrane cells. The coexistence of immune cells and mucous membrane epithelial cells is related to the development of a resistance to immunemediated apoptosis in epithelial cells, especially endometrial cells (117) . Over the course of the menstrual cycle phases, the level of MT expression fluctuates, reaching its highest level during the mid-secretory cycle phase when the endometrium is infiltrated by abundant dNK cells (117, 118) . During the implantation of an ectopic pregnancy in the tubal mucosa the increase in MT is accompanied by an increasing infiltration of immune cytotoxic cells (99, 119) . Similarly, during spontaneous abortion, when the decidua is infiltrated by abundant cytotoxic cells, MT expression increases (99).
MT expression is at a statistically significantly higher level at this time than during the mid-secretory cycle phase while the number of infiltrating dNK cells in the endometrium is statistically significantly higher than during the midsecretory cycle phase (118) . In the reproductive tract mucosa, changes in the number of infiltrating immune cells and alterations in their activity in both the endometrium and tubal mucosa accompany changes in MT expression. This indicates the possibility of alterations in the resistance to immune-mediated apoptosis in mucosal cells. Similarly, in ectopic endometrium, changes in the immune cytotoxic cell infiltrate (120) and the increasing activity of these cells accompany alterations in MT expression in both the stroma and the glandular epithelium (112, 117) . In the case of eutopic endometrium, MT expression is predominant in the glandular epithelium, whereas in ectopic endometrium, MT expression is predominant in the stroma.
In scar endometriosis resulting from cesarean section, where the activity of the immune cytotoxic cells is higher in comparison to the levels found in the endometrium during the mid-secretory cycle phase and in ovarian endometriosis, MT expression is also at its highest level (112) . The ability of a woman's reproductive system epithelial cells to develop a resistance to immune-mediated apoptosis is a feature that under normal physiological conditions enables the proper interaction between epithelial cells and immune cytotoxic cells as a mechanism to compensate for the increase in the activity of immune cells required for essential reproductive processes.
PERSPECTIVES
Multistep carcinogenesis is related to a breakdown in the immune response that enables tumor progression and dissemination. This breakdown is a crucial for tumor survival. MT's participation in geno-and cytotoxicity influences this process. The evaluation of MT expression in cancer and its stroma seems to correlate with the level of immune system inhibition in the canceradjacent stroma.
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